ScienCrown经导管植入式主动脉瓣膜系统

Search documents
惨遭控股股东减持,心泰医疗股价重挫12.75%!
Sou Hu Cai Jing· 2025-08-26 12:50
8月26日,港股的心泰医疗(02291.HK)重挫12.75%,报23.96港元/股,市值83.08亿港元,公司今日成交明显放量,单日 成交金额3.76亿港元,数亿元资金汹涌出逃。 消息面,心泰医疗公告称,公司获控股股东乐普医疗(300003.SZ)大幅减持,后者于8月26日通过大宗交易出售合共1114 万股心泰医疗H股,每股价格为22.79港元,占公司已发行股份总数的约3.21%。 本次减持后,乐普医疗将继续持有约2.69亿股心泰医疗的股份,占公司已发行股本约77.54%,彰显其对公司的坚定信心。 公告强调,本次减持不会对公司业务造成任何不利影响。乐普医疗对公司的业务运营充满信心,减持旨在提升公司股票的 流动性。 值得一提的是,今年上半年,由心泰医疗自主研发的TAVR产品——ScienCrown经导管植入式主动脉瓣膜系统成功开展上市 后全国多家临床中心首批植入。 业内人士认为,上述产品的商业化落地,也意味着国内在结构性心脏病治疗领域的创新实力迈上新台阶,相关医疗器械的 国产替代和升级将进一步加速,也助力公司的业绩走向新的台阶。 中信建投研报指出,心泰医疗在结构性心脏病领域布局全面,产品管线覆盖先心封堵器、心 ...
首批商业化植入!全球首款具有球扩瓣优势的自膨短瓣
思宇MedTech· 2025-05-27 10:52
Core Viewpoint - The article highlights the successful commercialization and clinical application of the ScienCrown transcatheter aortic valve replacement (TAVR) system developed by Lepu Medical Technology, marking a significant advancement in the treatment of aortic stenosis patients in China [2][5][10]. Company Overview - Lepu Medical Technology (Shanghai) Co., Ltd. is a leading innovator in the field of interventional medical devices for structural heart diseases, supported by the Shanghai Biomedical Investment Fund. The company went public on November 8, 2022, on the Hong Kong Stock Exchange under the stock code 02291.HK [17]. - The company focuses on the research, development, production, and marketing of interventional medical devices, with over 40 products listed and in development, covering congenital heart disease, stroke prevention, and valve treatment solutions [17]. Product Introduction - The ScienCrown TAVR system is the world's first and only self-expanding short valve product with balloon-expandable advantages, designed to address existing challenges in TAVR procedures [4][12]. - The product features 100% full release and retrieval capabilities, dual access routes, and innovative designs that significantly enhance clinical practice [4][12][15]. Clinical Application - The first commercial implantations of the ScienCrown valve have been successfully conducted in multiple clinical centers across China, demonstrating its effectiveness and safety [5][7]. - Clinical trial results indicate a procedural success rate of approximately 99.2% and a device success rate of about 98.4%, with low rates of paravalvular leak and no severe leaks reported [7][10]. Market Context - Aortic valve disease, particularly aortic stenosis (AS), is a common cardiovascular issue, especially among the elderly, with a prevalence of approximately 11.5% in patients over 60 years old [8][10]. - The number of patients with aortic stenosis and aortic regurgitation in China is projected to reach 9.3 million by 2025, with a compound annual growth rate of 2.6% from 2022 to 2025 [10].
红杉中国医疗成员企业再创多项“首个”记录|Healthcare View
红杉汇· 2025-04-29 11:30
金仕生物 全球首款预装干瓣Prostyle A® 获批上市 4月9日,金仕生物宣布由公司自主研发的 Prostyle A®经导管人工主动脉瓣膜置换系统-干法预装可回收输送 系统 获得国家药品监督管理局 (NMPA) 批准上市 ( 国械注准20253130729) 。 作为全球首款预装干瓣,金仕生物推出的新一代介入主动脉瓣Prostyle A®集成了众多瓣膜领域的前沿技 术,拥有干瓣技术、巧妙便捷的预装系统、卓越的瓣膜血流动力学性能和耐久性,优秀的输送性和通过 性,平稳的释放和可靠的锚定等特点。金仕生物自主创新的干瓣技术,在国内、欧洲、美国、日本等国家 享有专利保护。这一产品的出现,迎来中国TAVR的新时代 ——干瓣时代。 艾柯医疗 全新血流导向密网支架系统"Lattice COUPLE"成功获批 近日,艾柯医疗全新血流导向密网支架系统"Lattice COUPLE",成功获得国家药监局批准注册 ( 注册证编 号:国械注准20253130668) 。至此, 艾柯医疗成为神经介入行业首家拥有三张密网注册证的企业 。 微光医疗 FDA 首次批准中国高端腔内介入影像设备 4月11日,微光医疗宣布其两款冠脉OCT设备及 ...